Idvynso (doravirine/islatravir) HIV access guide: the first non-INSTI, tenofovir-free, two-drug regimen — PA criteria, payer coverage, switching protocols, and affordability

On April 21, 2026, the FDA approved Idvynso (doravirine 100 mg and islatravir 0.25 mg), a once-daily oral two-drug single-tablet regimen (STR) for the treatment of HIV-1 infection in adults to replace the current antiretroviral regimen in those who are virologically suppressed (HIV-1 RNA <50 copies/mL) on a stable antiretroviral regimen. The approval applies to patients with no history of virologic treatment failure and no known substitutions associated with resistance to doravirine.

Idvynso is the first and only non-integrase strand transfer inhibitor (INSTI), tenofovir-free, once-daily, complete two-drug regimen to demonstrate non-inferior efficacy in a head-to-head Phase 3 trial versus the three-drug regimen Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide). It introduces islatravir — a first-in-class nucleoside reverse transcriptase translocation inhibitor (NRTTI) — to the U.S. market.

For HIV access teams, infectious disease pharmacists, and payer strategists, Idvynso creates a new switching option that avoids INSTI-related weight gain and bone/renal toxicity concerns associated with tenofovir. But the switch-only indication, CYP3A drug interaction limitations, and contraindication with lamivudine/emtricitabine create specific access hurdles that this guide addresses.

This guide covers the FDA label, clinical evidence, prior authorization requirements, drug interaction management, affordability programs, and what to monitor next.

Short answer

How Idvynso differs from existing HIV STRs

Idvynso's positioning: a two-drug, INSTI-free, tenofovir-free option for patients who want to switch from a three-drug regimen. The trade-offs are a switch-only label (not yet approved for treatment-naïve patients), CYP3A drug interaction limitations, and contraindication with lamivudine/emtricitabine.

Clinical evidence: Trials 051 and 052

The FDA approval was based on two pivotal Phase 3 randomized, active-controlled, non-inferiority trials.

Trial 051 (NCT05631093)

• Adults virologically suppressed on their current ART regimen
• Randomized 2:1 to switch to doravirine/islatravir or remain on current baseline ART
• At week 48: 1% of Idvynso arm had HIV-1 RNA ≥50 copies/mL vs. 5% in the baseline arm (difference: −3.6%; 95% CI: −7.8 to −0.8)
• Met non-inferiority criterion

Trial 052 (NCT05630755)

• Adults virologically suppressed on Biktarvy (BIC/FTC/TAF)
• Randomized 2:1 to switch to doravirine/islatravir or remain on Biktarvy
• At week 48: 1% rate in both arms (difference: 0.9%; 95% CI: −1.9 to 2.9)
• Met non-inferiority criterion against the most widely prescribed HIV STR

Key access implication: Idvynso demonstrated non-inferiority against Biktarvy, which is the dominant HIV STR in the U.S. market. This head-to-head data strengthens the case for PA approval when switching from Biktarvy. Payers are unlikely to require step therapy through older regimens before approving Idvynso.

Treatment-naïve data (not yet approved)

A separate Phase 3 study presented at CROI 2026 showed that Idvynso worked as well as Biktarvy for people starting HIV treatment for the first time: at 48 weeks, 92% on Idvynso vs. 91% on Biktarvy had undetectable viral loads. Merck is expected to submit this data to the FDA for a treatment-naïve indication expansion.

Prior authorization requirements

PA for Idvynso is required by most commercial payers. The following documentation is typically needed:

Required documentation

1. Current viral suppression: HIV-1 RNA <50 copies/mL, documented by lab results within the past 3–6 months
2. Stable ART history: patient is on a stable antiretroviral regimen for at least 3 months
3. No virologic failure history: no documented episodes of HIV-1 RNA ≥200 copies/mL while on ART (some plans may use different thresholds)
4. No known doravirine resistance: no documented resistance substitutions associated with doravirine (per genotypic resistance testing)
5. No contraindicated concurrent medications: patient is not taking strong CYP3A inducers, lamivudine, or emtricitabine
6. ICD-10 codes:
   • B20 (Human immunodeficiency virus [HIV] disease)
   • Z21 (Asymptomatic human immunodeficiency virus infection status)

Payer-specific notes

Most payers classify Idvynso as a specialty pharmacy medication. As a newly launched product, formulary placement is still being established. Early signals:

• Commercial plans are reviewing Idvynso for specialty tier placement, typically alongside Biktarvy and Dovato
• Step therapy is unlikely given the switch-only indication, but some plans may require documented intolerance to or drug interaction with current ART before approving a switch to Idvynso
• Prior authorization processing times are typically 5–14 days for new-to-market HIV medications

Drug interaction limitations

Idvynso has specific drug interaction constraints that access teams must screen before PA submission.

Contraindications

1. Strong CYP3A inducers: carbamazepine, oxcarbazepine, phenytoin, phenobarbital, rifampin, rifapentine, St. John's wort, and others. These drugs decrease doravirine exposure and may reduce Idvynso efficacy.
2. Lamivudine (3TC) and emtricitabine (FTC): coadministration with these NRTIs is contraindicated because islatravir and 3TC/FTC compete for intracellular phosphorylation, which may reduce islatravir's antiviral activity.

Access implication: Many patients currently on Biktarvy (which contains FTC) or regimens containing 3TC/FTC will need their entire ART regimen changed — not just one component swapped — when switching to Idvynso. This is a critical counseling and PA documentation point. The PA submission should explicitly note that the patient's current regimen has been (or will be) fully discontinued upon Idvynso initiation.

Dose adjustment with rifabutin

For patients requiring rifabutin (a moderate CYP3A inducer used for mycobacterial infections), the Idvynso label includes a dosage adjustment: the islatravir component should be doubled to 0.5 mg (by taking an additional islatravir tablet) for the duration of rifabutin coadministration. Access teams should verify this with the prescriber and document it in the PA.

Hepatitis B coinfection

Idvynso does not provide adequate coverage for hepatitis B virus (HBV). Patients coinfected with HIV/HBV who are currently on a regimen containing tenofovir (TAF or TDF) or lamivudine/emtricitabine — which have anti-HBV activity — may experience HBV reactivation if switched to Idvynso.

Access implication: PA submissions should document the patient's HBV status. Patients with active HBV coinfection should not be switched to Idvynso unless an alternative HBV treatment plan is in place.

Pricing and affordability

WAC pricing

• Wholesale acquisition cost (WAC): ~$4,455 for a 30-day supply
• This is approximately $200 more than Biktarvy and $1,000 more than Dovato at WAC
• Actual acquisition cost (AAC) and plan-level net costs will vary based on rebate negotiations

Merck Access Program

Merck offers comprehensive support for patients prescribed Idvynso:

• Insurance verification: Merck Access Program staff verify individual insurance coverage and out-of-pocket costs
• Co-pay assistance: for eligible commercially insured patients, co-pay assistance reduces out-of-pocket costs (specific co-pay amounts vary by plan)
• Patient assistance: for uninsured or underinsured income-eligible patients
• Contact: 1-877-709-4455 or merckaccessprogram-Idvynso.com

ADAP and Ryan White coverage

State AIDS Drug Assistance Programs (ADAPs) and Ryan White programs are expected to add Idvynso to their formularies, though timing varies by state. ADAP formulary updates typically occur quarterly. Access teams should:

• Check the state ADAP formulary for Idvynso inclusion
• Monitor for ADAP formulary committee meeting agendas that include Idvynso review
• Be aware that ADAPs are under significant budget and political pressure in 2026, which may delay formulary additions

Medicare Part D

Idvynso will be covered under Medicare Part D. As a brand-name specialty drug, it will be subject to the Part D specialty tier. The Inflation Reduction Act's $2,000 annual out-of-pocket cap (effective 2025) applies, meaning Medicare beneficiaries will not pay more than $2,000/year for all Part D drugs combined.

Safety monitoring

The most common adverse reactions in clinical trials (≥2% of patients):

• Diarrhea
• Dizziness
• Fatigue
• Headache
• Abnormal dreams (associated with doravirine)

Serious but rare risks include:

• Severe skin reactions (including Stevens-Johnson syndrome and toxic epidermal necrolysis)
• Immune reconstitution inflammatory syndrome (IRIS)
• Hepatotoxicity (primarily in patients with underlying liver disease)

Routine monitoring for patients on Idvynso includes:

• HIV-1 RNA at baseline, 4 weeks post-switch, and then per standard of care (every 3–6 months)
• Renal function (especially important for patients switching from tenofovir-containing regimens)
• Hepatic function
• Lipid panel (INSTI discontinuation may affect lipid profiles)

What to monitor next

1. Treatment-naïve indication: Merck has Phase 3 data demonstrating efficacy in treatment-naïve patients. A supplemental NDA is expected. Approval would significantly expand the eligible patient population and remove the switch-only PA barrier.

2. ADAP formulary additions: State-by-state ADAP formulary decisions will determine access for uninsured and underinsured patients. Monitor quarterly ADAP updates.

3. Rebate and net pricing: Idvynso's WAC premium over Biktarvy may limit formulary adoption unless Merck offers competitive rebates. Watch PBM formulary exclusion lists for 2027.

4. Long-acting HIV pipeline: Monthly, bimonthly, and longer-acting injectable HIV regimens are in development. Idvynso's oral daily positioning may face competition from long-acting options if patients prefer less frequent dosing.

5. Islatravir safety signal monitoring: Islatravir had a previous clinical hold (2021–2022) due to decreases in total lymphocyte and CD4+ T-cell counts at higher doses. The approved 0.25 mg dose did not show this signal in Phase 3, but post-marketing surveillance is ongoing. FDA may issue additional safety communications.

6. Drug interaction updates: As islatravir is a new molecular entity, additional drug interaction studies may yield updated dosing recommendations. Monitor for prescribing information updates.

Sources

• Merck. FDA Approves Merck's Once-Daily Idvynso (doravirine/islatravir) News Release (April 21, 2026). merck.com/news
• FDA. Idvynso Prescribing Information (April 2026). accessdata.fda.gov
• Drugs.com. FDA Approves Idvynso (doravirine and islatravir) for the Treatment of HIV-1 Infection in Adults (April 21, 2026). drugs.com/newdrugs
• HIV i-Base. US FDA and Japan Approve New Once-Daily Oral HIV Combination (April 21, 2026). i-base.info/htb/53742
• POZ. FDA Approves New HIV Combo Pill Idvynso (April 22, 2026). poz.com
• Managed Healthcare Executive. FDA Approves Antiretroviral Idvynso for Adults with HIV (April 2026). managedhealthcareexecutive.com
• TheBody. Idvynso: New HIV Medication Approved by the FDA (April 2026). thebody.com
• Georgetown University School of Medicine. FDA Approves New HIV Treatment Option (2026). medicine.georgetown.edu
• NIH. FDA-Approved HIV Medicines. hivinfo.nih.gov
• ContagionLive. FDA Approves Doravirine/Islatravir, a First-in-Class 2-Drug HIV Regimen (April 2026). contagionlive.com